Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Genflow Biosciences - Total Voting Rights | - | RNS | ||
28.05. | Genflow Biosciences unterzeichnet F&E-Abkommen mit belgischer CER Groupe | 1 | Investing.com Deutsch | ||
28.05. | Genflow Biosciences inks R&D pact with Belgian CER Groupe | 1 | Investing.com | ||
28.05. | Genflow Biosciences PLC: Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration | 328 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce... ► Artikel lesen | |
28.05. | Genflow Biosciences - Genflow Signs Master Services Agreement | - | RNS | ||
22.05. | Genflow Biosciences PLC Announces AGM Notice | 218 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / May 22, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused... ► Artikel lesen | |
22.05. | Genflow Biosciences sets date for annual meeting | 3 | Investing.com | ||
22.05. | Genflow Biosciences - AGM Notice | 1 | RNS | ||
GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
15.05. | Genflow Biosciences advances SIRT6 patent in Japan | 2 | Investing.com | ||
15.05. | Genflow Biosciences PLC Announces Key SIRT6 Patent Application | 196 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces... ► Artikel lesen | |
15.05. | Genflow Biosciences - Key SIRT6 Patent Application | 1 | RNS | ||
12.05. | Genflow Biosciences PLC Announces Holding(s) in Company | 214 | ACCESS Newswire | Please note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held... ► Artikel lesen | |
09.05. | Genflow Biosciences PLC Announces Share Subscription, Director's Dealing and Update | 218 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
09.05. | Genflow Biosciences - Share Subscription, Director's Dealing and Update | 2 | RNS | ||
30.04. | Genflow Biosciences PLC Announces Final Results | 247 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
30.04. | Genflow Biosciences treibt Langlebigkeitsforschung mit neuen Kooperationen voran | 3 | Investing.com Deutsch | ||
30.04. | Genflow Biosciences advances longevity research with new collaborations and grants | 2 | Investing.com | ||
30.04. | Genflow Biosciences - Final Results | 1 | RNS | ||
14.04. | Genflow Biosciences enters AI gene therapy research deal | 3 | Investing.com | ||
14.04. | Genflow Biosciences schließt KI-Forschungspartnerschaft für Gentherapie ab | 1 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
BIONTECH | 99,25 | +1,79 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
QIAGEN | 40,320 | -0,01 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |